Drugs / Povetacicept
Povetacicept
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05034484 | Nov 2021 → Feb 2023 | — | Alpine Immune Sciences, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05757570 | Jul 2023 → Jul 2026 overdue | autoimmune hemolytic anemia, warm type, autoimmune thrombocytopenic purpura, cold agglutinin disease | Alpine Immune Sciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05732402 | Mar 2023 → Mar 2028 expected | IgA glomerulonephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, lupus nephritis, membranous glomerulonephritis | Alpine Immune Sciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07501702 | May 2026 → Mar 2029 expected | generalized myasthenia gravis | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07204275 | Sep 2025 → Dec 2028 expected | idiopathic membranous glomerulonephritis | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06564142 | Aug 2024 → Jan 2028 expected | IgA glomerulonephritis | Alpine Immune Sciences, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Vertex Pharmaceuticals Incorporated | Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy vrtx.com ↗ |
| 2026-03-09 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy vrtx.com ↗ |
| 2025-11-08 | Vertex Pharmaceuticals Incorporated | Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week vrtx.com ↗ |
| 2025-10-17 | Vertex Pharmaceuticals Incorporated | Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week vrtx.com ↗ |
| 2025-06-23 | Vertex Pharmaceuticals Incorporated | Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea vrtx.com ↗ |
| 2025-01-10 | Vertex Pharmaceuticals Incorporated | Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore vrtx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Povetacicept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564142 ↗ |
| Known as | ALPN-303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05034484 ↗ |
| Known as | Variant tnf receptor domain | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095306 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095306 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection every 4 weeks” NCT05732402 ↗ |